Immunosuppressive Drugs and Highly Active Antiretroviral Therapy: Pharmacokinetic Interactions;Médicaments immunosuppresseurs et antirétroviraux: Une association riche en interactions

Therapie

Volumn 62, Issue 4, 2007, Pages 327-335

  Moretto, Johnny ^a   Bessard, Germain ^a   Stanke Labesque, Françoise ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Drug interactions; HIV; Immunosuppressive drugs; Transplantation

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CYCLOSPORIN; CYTOCHROME; DARUNAVIR; EFAVIRENZ; EVEROLIMUS; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; RAPAMYCIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

BIOTRANSFORMATION; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; ANIMAL; DRUG INTERACTION; REVIEW;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOTRANSFORMATION; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 38449100133     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007060     Document Type: Conference Paper

References (43)

1. Krikorian S, Rudorf D. Drug-Drug Interactions and HIV Therapy: what should Pharmacists know? Journal of Pharmacy Practice 2005; 18: 278-94
2. Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98: 79-85
3. Rowland P, Blaney FE, Smyth FG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem. 2006; 281: 7614-22
4. Dictionnaire Vidal 2006
5. Yéni P. Prise en charge médicale des personnes infectées par le VIH. Medecine-Sciences, Flammarion, 2006
6. Li X, Chan WK. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv Drug Deliv Rev 1999; 39: 81-103
7. Gerber JG, Acosta EP. Therapeutic drug in the treatment of HIV-infection. J Clin Virol 2003, 27: 117-28
8. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78: 664-74
9. http://www.hiv-druginteractions.org
10. Back D, Sekar V, Lefebvre E, et al. Use of TMC114 in combination with other drugs : guidance from pharmacokinetic studies. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 2005
11. Cornaire G, Woodley J, Houin G. Influence des transporteurs d'efflux sur le passage intestinal des médicaments. Revue Française des Laboratoires 2002, No 339
12. Izzedine H, Launay-Vacher V, Baumelou A, et al. Antiretroviral and immunosuppressive drug-drug interactions: An update. Kidney Int 2004; 66: 532-41
13. Haas DW. Pharmacogenomics of antiretroviral therapy. Drug Dev Res 2004; 62: 213-20
14. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006. 44: 119-25
15. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192: 1931-42
16. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1 infected patient. Clin Pharmacol Ther 2004; 75: 558-68
17. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207-17
18. Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 2003; 39, 664-78
19. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-56
20. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54
21. Yu S, Wu L, Jin J et al. Influence of CYP3A5 Gene Polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006; 81: 46-51
22. Jeong H, Chiou WL. Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 2006; 36: 1-13
23. Formica R, Lorber K, Friedman A, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36 495-9
24. Sadaba B. Campanero MA, Quetglas EG, et al. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36, 3226-8
25. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005; 78: 317-321
26. Kuypers DR, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate glucuronosyl-transferase. Clin Pharmacol Ther 2005; 78: 81-8
27. Samuel D, Duclos-Vallee JC, Teicher E, et al. Liver transplantation in patients with HIV infection. J Hepatol 2003; 39: 3-6
28. Fishman J, Rubin R. Solid Organ Transplantation in HIV-infected Individuals: Obstacles and Opportunities. Transplantation Proc 2001; 33: 1310-4
29. Lewden C, Jougla E, Alioum A, et al. Number of deaths among HIV-infected adults in France, three-source capture-recapture estimation. Epidemiol Infect 2006; 134: 1345-52
30. Markus T. Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity. Mol Med Today 1995; 1(6): 287-91
31. Fumero E, Garcia F, Gatell JM. Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother 2004; 53: 415-417
32. Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841-5
33. Yang Z, Peng Y, Wang S. Immunosuppressants: pharmacokinetcs, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. Clin. Applied Immunol 2005; 5: 405-30
34. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 13-7
35. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected Patients. Liver Transpl 2004; 10: 939-44
36. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine [letter]. Ann Intern Med 1998; 129: 915-6
37. Tseng A, Nguyen ME, Cardella C, et al. Probable interaction between efavirenz and cyclosporine. AIDS 2002; 16: 505-6
38. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of Coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954-60
39. Neff G, Tzakes A, Safdar K, et al. Liver transplantation in HPV, complex pharmacokinetic interactions between tacrolimus and highly active antiretroviral therapy. [abstract] 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003
40. Hardy G, Stanke-Labesque F, Contamin C, et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 2004; 60: 603-5
41. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report. Liver Transpl 2002; 8(9): 838-40
42. Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002; 55: 41-52
43. Margolis D, Kewn S, Jason J, et al. The Addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 45-9